Experts estimate that 22 million people around the world and more than 8 million Americans will be afflicted with Alzheimer’s Disease (AD) by 2025. Due to the changing demographics, the number of people with AD is expected to grow quickly. The number of AD patients is expected to grow at an annual rate of 17.5%.

Leading AD drugs are reversible cholinesterase inhibitors: Aricept®, Razadyne®, Exelon®, and Cognex®. This approach has proven to be inadequate, providing more of a band-aid than substantive relief for AD patients, with significant side effects of nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, and anorexia.

These drug regimens may benefit from our anti-nausea drug, Zindol®, under development, and its dietary supplement counterpart, Zindol® DS.

Aphios is developing intravenous and oral formulations of APH-1104, a potent protein kinase C (PKC) modulator, to treat AD.

• APH-1104 activates PKC in order to ameliorate AD pathophysiology and cognitive impairment. APH-1104 is also neuroprotective via activation of PKC isoforms, downregulation of pro-inflammatory factors and angiogenic processes, and the conversion of beta-amyloid into its soluble form, sAPPα.

We are also developing other enhanced Central Nervous System (CNS) therapeutics for marijuana addiction, cancer pain, AIDS cachexia or wasting, glaucoma, multiple sclerosis and mild to moderate depression.

• Xantol™ is an enhanced St. John’s Wort botanical drug, for mild to moderate depression.
• APH-0802 is an oral nanoformulation of Δ9-THC, the active pharmaceutical ingredient of Cannabis sativa (marijuana) for marijuana addiction, pain in cancer and AIDS patients, cachexia in cancer and HIV/AIDS patients as well as multiple sclerosis and several developing indications.
• APH-1403 is a Multiple Sclerosis disease-modifying therapeutic that activates the PPAR-γ pathway expressing both anti-inflammatory and neuroprotective bioactivities